VAPOTHERM INC - VAPO STOCK NEWS

Vapotherm (NYSE: VAPO) has received a notice from the New York Stock Exchange (NYSE) regarding non-compliance with continued listing standards, specifically due to its average stock price falling below $1.00 per share for 30 consecutive trading days, recorded at $0.94 as of March 14, 2023. The company has a six-month cure period to regain compliance by achieving a closing price of at least $1.00. Despite this, the current situation does not impact Vapotherm's business operations or its SEC reporting obligations. The stock will trade under the symbol VAPO with the designation '.BC' until compliance is regained.

Vapotherm, Inc. (NYSE: VAPO) reported a total revenue of $18.7 million for Q4 2022, reflecting a 16.1% decline from the previous year. For the fiscal year, revenue was $66.8 million, a 41% drop. The decrease is attributed to reduced demand for products linked to COVID-related hospitalizations. The company successfully completed its manufacturing transition to Mexico and launched the HVT 2.0 platform. Net loss for Q4 was $21.4 million, or $0.78 per share, while the total net loss for the year reached $113.3 million, or $4.24 per share. Looking ahead, VAPO anticipates revenue between $77 million and $79 million for 2023.

Vapotherm, Inc. (NYSE: VAPO) announced the closing of a private placement on February 10, 2023, raising approximately $23.0 million. The offering included the issuance of 17,502,244 shares of common stock and pre-funded warrants allowing for the purchase of an additional 4,402,508 shares at an exercise price of $0.001 each. Accompanying warrants to purchase one share for every share purchased were also issued at an exercise price of $1.17, with a five-year lifespan. Proceeds from this placement will primarily support sales, marketing, and general corporate expenses.

Vapotherm, Inc. (NYSE: VAPO) announced a private placement financing, securing approximately $23.0 million in gross proceeds. The agreement involves issuing 17,502,244 shares of common stock and pre-funded warrants for additional shares. The warrants will have exercise prices of $1.17 and a five-year lifespan. Proceeds will primarily support sales, marketing, and general corporate purposes. This offering is expected to close on February 10, 2023. Additionally, Vapotherm plans to file a registration statement with the SEC for resale of the offered securities.

Vapotherm, Inc. (NYSE: VAPO) announced preliminary unaudited financial results for Q4 and full year 2022. Q4 net revenue is estimated between $18.4 million and $18.7 million, with gross margin expected at 27-28%. Operating expenses range from $22.8 million to $23.0 million. For the full year 2022, net revenue is anticipated to be $66.0 million to $67.0 million, with gross margin around 25-26%. The company reported cash and equivalents at approximately $15.7 million as of December 31, 2022. Looking ahead, VAPO expects 2023 revenue between $77 million and $79 million, improving gross margin to 48-50%. The company is also addressing prior NYSE delisting notices successfully.

Vapotherm, Inc. (NYSE: VAPO) has received a notification from NYSE regarding non-compliance with listing standards due to its stock price falling below $1.00 per share. As of November 29, 2022, the average closing price was $0.98. Vapotherm has six months to regain compliance by maintaining a closing price above $1.00. On December 5, 2022, the stock price was $1.62, meeting the requirements. This notification does not impact business operations or debt agreements and will not affect trading, though the stock will carry a '.BC' designation during the compliance period.

On November 21, 2022, Vapotherm (NYSE: VAPO) announced the Third Amendment to its Loan and Security Agreement with SLR Investment Corp, aimed at providing financial flexibility. Key provisions include a reduction of the liquidity covenant to $5 million and an option to pay some interest in kind, allowing the company to conserve cash. Following these changes, Vapotherm's ability to meet revenue targets has been modified, and the amendment is viewed as a step towards achieving profitability and reducing financial stress amid ongoing operations.

Vapotherm (NYSE: VAPO) reported third quarter 2022 revenues of $13.5 million, down 64.5% year-over-year, impacted by lower demand compared to the prior year's COVID surge. U.S. disposable revenue saw a modest 19.6% increase from the previous quarter, reaching $9.5 million. The company expects 2022 revenues to range between $64 million and $66 million, reflecting a light flu season. Operating expenses decreased significantly to between $94 million and $96 million, while gross margin is projected between 22% and 24%. Net loss for Q3 2022 was $26.2 million, or $0.98 per share.